pharmaphorum| News & views on pharma and biotech’s evolving future

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

R&D

Knowledge Quarter, King's Cross, London, UK

From physics to pharma: How Aqemia is reinventing the future...

The UK life sciences sector has long been a crucible for innovation, blending academic excellence with a thriving ecosystem of biotech and pharmaceutical enterprises.

Spotlight on

Frontiers Health 2025

Oncology

Interview at ESMO 2025 with Sandeep Reddy, Immunity Bio

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

News

Halda Therapeutics' president and chief executive, Christian Schade

J&J swoops on cancer biotech Halda with $3bn takeover deal

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy Halda Therapeutics and its RIPTAC anticancer platform.

Featured Content

R&D

From physics to pharma: How Aqemia is reinventing the future...

The UK life sciences sector has long been a crucible for innovation, blending academic excellence with a thriving ecosystem of biotech and pharmaceutical enterprises.

Spotlight on

Frontiers Health 2025

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Oncology

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

Newsletters and Deep Dive
digital magazine

Latest News

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

J&J swoops on cancer biotech Halda with $3bn takeover deal

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy Halda Therapeutics and its RIPTAC anticancer platform.

News

BMS, J&J give up on milvexian for acute coronary syndrome

BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.

News

Filmmaker helps AbbVie spread the word about leukaemia

AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.

Views & Analysis

R&D

From physics to pharma: How Aqemia is reinventing the future...

The UK life sciences sector has long been a crucible for innovation, blending academic excellence with a thriving ecosystem of biotech and pharmaceutical enterprises.

Oncology

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

Digital

Pharma’s new gatekeeper: AI’s rising role

The AI bouncer guarding the door of healthcare information isn’t going anywhere and isn’t changing its standards.

Oncology

Interview at ESMO 2025 with Tadaaki Taniguchi

ESMO25: On next-generation bispecifics, with Tadaaki Taniguc...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.

Deep Dive

Patients

Patients and Partnerships 2025

Patients

How DTP became pharma’s newest battleground

Patients

How to land a deal with big pharma

Patients

Beyond being heard: The patient voice as a force for change

White Papers & Webinar

Sales & Marketing

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

R&D

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

Digital

Sponsored

Future proofing production: Implementing AI in pharmaceutica...

Read Zühlke’s new white paper, ‘Future Proof Production: Implementing AI in pharmaceutical manufacturing’ today.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Tracking studies get smarter: AI meets human intelligence

Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market